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Mitochondrial DNA (mtDNA) is considered a candidate modifier factor for 
neuro-degenerative disorders. The most common type of ataxia is Friedreich’s 
ataxia (FA). The aim of this study was to investigate different parts of mtDNA 
in 20 Iranian FA patients and 80 age-matched controls by polymerase chain 
reaction (PCR) and automated DNA sequencing methods to find any probable 
point mutations involved in the pathogenesis of FA. 
Materials and Methods
We identified 13 nucleotide substitutions including A3505G, T3335C, G3421A, 
G8251A, A8563G, A8563G, G8584A, T8614C, T8598C, C8684T, A8701G, 
G8994A and A9024G. 
Results
Twelve of 13 nucleotide substitutions had already been reported as 
polymorphism. One of the nucleotide substitutions (A9024G) had not been 
reported before. The A9024G nucleotide substitution does not change its 
amino acid. The controls were also investigated for this polymorphism which 
was found in two of them (2.5%). 
Conclusion
None of the mutations found in this study can affect the clinical manifestations 
of FA. This survey also provides evidence that the mtDNA A9024G allele is 
a new nonpathogenic polymorphism. We suggest follow-up studies for this 
polymorphism in different populations.
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Introduction
Mitochondrial genome is exclusively maternally inherited, does exhibit high 
mutation and mutation fixation rates (1). Modifier genes are defined on the basis 
of their ability to modulate the clinical phenotype of individuals with monogenic 
and multigenic disease (2). Mitochondrial DNA (mtDNA) could be considered a 
candidate modifier factor for neurodegenerative disorders, since mitochondrial 
oxidative stress is thought to be involved in the pathogenesis of degenerative 
disorders (3,4). The mutation rate for mtDNA is 10 times higher than that of 
nuclear genomic DNA  (2). Many mtDNA diseases present with neurological 
symptoms and signs, but the clinical features are often non-specific and diffuse, 
and mitochondrial diseases have frequently been misdiagnosed when only 
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clinical abnormalities are considered  (5). Friedreich 
ataxia (FA, OMIM# 229300) is an autosomal recessive 
ataxia resulting from a mutation of a gene locus on 
Chromosome 9q13-q21.1 (6).  Clinical diagnostic 
criteria for typical cases basically are Progressive limb 
and gait ataxia develops before the age of 30 years 
(7,8). Lower extremity tendon reflexes are absent and 
evidence of axonal sensory neuropathy is noted (7-9). 
Dysarthria, areflexia, motor weakness of the lower 
extremities, extensor plantar responses, and distal loss 
of joint position and vibration senses are not found in 
all patients within the first 5 years, but are eventually 
universal. Foot deformity, scoliosis, diabetes mellitus, and 
cardiac involvement are other common characteristics. 
Clinical evidence of ventricular hypertrophy, systolic 
ejection murmurs, and third or fourth heart sounds may 
be noted (9-11). Detected in about 96% of FA patients 
an expanded GAA trinucleotide repeat in intron 1 of 
the gene X25 that encodes a 210 amino acid protein, 
Frataxin, which is a nuclear-encoded protein located 
within mitochondrial inner membrane and crests (12). 
Frataxin is a component of the human Fe/S cluster (ISC) 
assembly machinery and it plays role in the maturation 
of both mitochondrial and cytosolic Fe/S proteins 
and also in heme biosynthesis (2,13). Recently, it has 
been shown that frataxin interacts with mitochondrial 
electron transport chain proteins (2,14). Excess iron in 
mitochondria of FA patients can cause mitochondrial 
dysfunction through irreversible oxidative damage. 
Iron is well-known as catalyst of free radicals (2). 
Patients with FA have a lower rate of mitochondrial 
ATP production (15). Following the symptoms, failure 
in ATP production and presence of free radicals in 
mitochondria of patients with FA was the reason for 
us to investigate MT-ATP8 (ATP synthase subunit F0 
8), MT-ATP6 (ATP synthase subunit F0 6), and highly 
mutative genes like; MT-LTI (tRNALeucine1(UUA/
G)) , MT-NDI (NADH Dehydrogenase subunit 1), 
MT-COII (Cytochrome coxidase subunit II), MT-TK 
(tRNALysine), in 20 Iranian FA patients (7 female 
and 13 male ) from 18 unrelated families, by PCR 
and automated DNA sequencing to find any probable 
point mutation that can be involved as an adjunct in the 
pathogenesis of FA.
Materials and Methods
20 patients were chosen randomly who had clinically 
and genetically diagnosed to have FA according to the 
criteria of Harding (16) and Geffroy et al. (17). All 
individuals included in this study were informed on the 
aims of the study and gave their informed consents to 
the genetic analysis. We performed mutations screening 
of MT-LTI, MT-NDI, MT-COII, MT-TK, MT-ATP8 
and MT-ATP6. Peripheral blood samples were obtained 
and DNA was purified after lyses of white blood cells 
by use of DNA extraction kit. (Diatom DNA Extraction 
Kit, Genefanavaran, Tehran). PCR amplification was 
carried out in a final volume of 50 µl containing 200-
300 ng total DNA, 10 pmol each primers, 2.5 mM 
MgCl2, 200 µM of each dNTP, 5µl l of 10X PCR buffer 
and 2 Units Taq DNA polymerase. (Roche Applied 
Science)Two sets of primer used are as follows; Primer 
ONPF25(8161-8180 nt) 5’ -CTA  CGG  TCA  ATG 
CTC  TGA  AA -3’,ONPR185 (9239-9219 nt) 5-’ 
TAC  TAT  ATG  ATA  GGC  ATG  TGA - 3’,These 
primers amplified a 1078 bp sequence encompassing 
of MT-COII, MT-NC7, MT-TK(tRNALys), MT-ATP8 
and MT-ATP6.Another pair of primers is ; ONPF82 
(3187-3206 nt) 5’- CTC  AAC  TTA  GTA  TTA  TAC 
CC-3’, ONPR164(3550-3530nt)  5’ -GAT  GGT  GAG 
AGC  TAA GGT  CG -3’ were used to amplify a 363 
bp sequence of  MT-TL1(tRNALeu1(UUA/G). The 
PCR reactions for amplification of first fragment were 
performed in a thermal cycler (MWG-Biotech Primus, 
Germany) for 35 cycles with denaturation at 94ºС for 
1΄ (min), primer annealing at 55ºС for 1΄ (min) and 
primer extension at 72ºС for 1΄ (min). The amplified 
fragments were separated by gel electrophoresis in 
1.5% agarose and for TL1 fragment were performed for 
35 cycles with denaturation at 94ºС for 1΄ (min), primer 
annealing at 60ºС for 1΄ (min) and primer extension 
at 72ºС for 35΄΄ (sec). The amplified fragments were 
separated by gel electrophoresis in 1.5% agarose. The 
nucleotide sequences of the amplicons were directly 
determined by automated sequencing 3700 ABI 
machine, using primer ONPF25, ONPF82 (Macrogene 
Seoul, Korea). The obtained mtDNA sequences were 
aligned with a multiple sequence alignment interface 
CLUSTAL_X with comparison to revised Cambridge 
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reference Sequence (rCRS).
Results
We have identified 13 different point mutations in 40% 
of our FA patients( 15% female, 25% male) on; MT-
LTI tRNALeu(UUA/G) , MT-NDI ,MT-COII , MT-
TK (tRNALys), MT-ATP8 and MT-ATP6 comparing 
with human mitochondrial DNA rCRS. Out of this 
13 different point mutations: 57.14% of them were 
observed on MT-ATP6, 21.42% of them were found on 
MT-NDI, 7.14% of them were occurred on MT-COII 
and, 14% of them were noted on MT-ATP8. One of the 
mentioned point mutations (table 1) (18-30) were same 
in two different patients, G 8251 A and A9024G has 
been reported for the first time.
Discussion
Iron accumulation in the mitochondria of patients with 
FA would result in hypersensitivity to oxidative stress 
as a consequence of fenton reaction (Fe2+ production of 
hydroxyl radicals),as reactive oxygen species (ROS) are 
continuously generated by the respiratory chain, they 
may have cause significant oxidative damage to mtDNA 
(mtDNA deletions and mutations) if not efficiently 
eliminated (2). Considering the symptoms of FA including 
progressive gait and limb ataxia, dysarthria, nystagmus, 
hypertrophic cardiomyopathy (7,10), FA patients have 
also a lower rate of ATP production (14). We expected 
to find point mutations related to pathogenesis of FA in 
MT-ATP8, MT-ATP6, and highly mutative genes like; 
MT-LTI, MT-NDI, MT-COII and MT-TK. However 13 
different mutations had been noted in 40% of the Iranian 
FA patients (table1), but our results showed that 12 
point mutations out of 13 have been reported before as 
polymorphisms. Only A9024G mutation was found for 
the first time in this study. Interpretation of the mtDNA 
sequence data can be extremely difficult because 
mtDNA is highly polymorphic and it is often difficult 
and time consuming to establish whether a mutation is 
pathogenic or not, particularly if the base change has 
not been reported before. Of course, several canonical 
criteria suggest that a novel base change is pathogenic: 
1) The base change must affect a site that has been 
conserved during evolution. 2) The mutation should 
be absent in normal controls. 3) The mutation must 
not be a known polymorphism (as described by one of 
the established sequence data bases). 4) The mutation 
should be reported in several pedigrees with similar 
phenotypes. 5) There must be a correlation between the 
levels of mutated mtDNA and severity of symptoms. 6) 
Deleterious mutations are usually (but not exclusively) 
heteroplasmic. This implies that the mutation occurred 
recently and did not have time to “fix”in the female line, 
or that there was selection against fixation acting at the 
level of the organism. 7) There is a correlation between 
the levels of mutated mtDNA and the occurrence of 
respiratory chain deficiency in individual muscle fiber 
segments or in cybrid cell lines. 8) Analysis of cybrid 
cell lines demonstrates that the mtDNA mutation alone 
is sufficient to cause a respiratory chain deficiency. 
These stringent criteria depend upon a good knowledge 
of the polymorphic sites in the background population. 
Thus, known polymorphic sites could be useful. In 
the present investigation, two criteria were applied to 
determine whether A9024G is pathogenic or not. The 
mutation was present in 2.5% of normal controls with 
the same ethnic origin and, according to established 
sequence data bases; the new base change was not a 
previously  known polymorphism. Our data suggest that 
A9024G is a new  nonpathogenic polymorphism in the 
Iranian population. To confirm whether this substitution 
is a polymorphism or a mutation, follow-up studies 
are needed using other criteria applied to different 
populations.
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